Journal Article
. 2014 May; 2:3.
doi: 10.1186/2051-1426-2-3.

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

Stefani Spranger 1 Holly K Koblish 2 Brendan Horton 1 Peggy A Scherle 2 Robert Newton 2 Thomas F Gajewski 3 
  • PMID: 24829760
  •     50 References
  •     258 citations


Background: Blockade of immune inhibitory pathways is emerging as an important therapeutic modality for the treatment of cancer. Single agent treatments have partial anti-tumor activity in preclinical models and in human cancer patients. Inasmuch as the tumor microenvironment shows evidence of multiple immune inhibitory mechanisms present concurrently, it has been reasoned that combination therapies may be required for optimal therapeutic effect.

Methods: To test this notion, we utilized permutations of anti-CTLA-4 mAb, anti-PD-L1 mAb, and/or the IDO inhibitor INCB23843 in the murine B16.SIY melanoma model.

Results: All three combinations showed markedly improved tumor control over single treatments, with many mice achieving complete tumor rejection. This effect was seen in the absence of vaccination or adoptive T cell therapy. The mechanism of synergy was investigated to examine the priming versus effector phase of the anti-tumor immune response. Only a minimal increase in priming of anti-tumor T cells was observed at early time points in the tumor-draining lymph nodes (TdLN). In contrast, as early as three days after therapy initiation, a marked increase in the capacity of tumor-infiltrating CD8(+) T cells to produce IL-2 and to proliferate was found in all groups treated with the effective combinations. Treatment of mice with FTY720 to block new T cell trafficking from secondary lymphoid structures still enabled restoration of IL-2 production and proliferation by intratumoral T cells, and also retained most of the tumor growth control.

Conclusions: Our data suggest that the therapeutic effect of these immunotherapies was mainly mediated through direct reactivation of T cells in situ. These three combinations are attractive to pursue clinically, and the ability of intratumoral CD8(+) T cells to produce IL-2 and to proliferate could be an important biomarker to integrate into clinical studies.

Keywords: Anti-CLTA-4; Combinatorial immunotherapy; IDO inhibitor; Immune inhibitory pathways; PD-1/PD-L1; T cell anergy/exhaustion; Tumor microenvironment; Tumor-infiltrating lymphocytes.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Karl S Peggs, Sergio A Quezada, James P Allison.
Immunol Rev, 2008 Sep 02; 224. PMID: 18759925
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
Helena Harlin, Yuru Meng, +5 authors, Thomas F Gajewski.
Cancer Res, 2009 Mar 19; 69(7). PMID: 19293190    Free PMC article.
Highly Cited.
Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.
A L Mellor, J Sivakumar, +4 authors, D H Munn.
Nat Immunol, 2001 Mar 29; 2(1). PMID: 11135580
Highly Cited.
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
M A Markiewicz, F Fallarino, A Ashikari, T F Gajewski.
Int Immunol, 2001 Apr 20; 13(5). PMID: 11312250
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
Liza B John, Linda J Howland, +10 authors, Phillip K Darcy.
Cancer Res, 2012 Feb 09; 72(7). PMID: 22315352
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
Rational combinations of immunotherapeutics that target discrete pathways.
Stefani Spranger, Thomas Gajewski.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829752    Free PMC article.
Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells.
Naoko Imai, Hiroaki Ikeda, Isao Tawara, Hiroshi Shiku.
Eur J Immunol, 2008 Dec 18; 39(1). PMID: 19089817
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu.
Nat Immunol, 2013 Sep 21; 14(10). PMID: 24048123    Free PMC article.
Highly Cited. Review.
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
Miguel-Angel Perales, Jianda Yuan, +15 authors, Jedd D Wolchok.
Mol Ther, 2008 Sep 18; 16(12). PMID: 18797450    Free PMC article.
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.
Yan Zheng, Yuanyuan Zha, +2 authors, Thomas F Gajewski.
J Exp Med, 2012 Nov 07; 209(12). PMID: 23129747    Free PMC article.
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
Shin Foong Ngiow, Bianca von Scheidt, +3 authors, Mark J Smyth.
Cancer Res, 2011 Mar 25; 71(10). PMID: 21430066
Highly Cited.
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
Yoshiko Iwai, Seigo Terawaki, Tasuku Honjo.
Int Immunol, 2004 Dec 22; 17(2). PMID: 15611321
Highly Cited.
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
Christian Blank, Ian Brown, +4 authors, Thomas F Gajewski.
Cancer Res, 2004 Feb 12; 64(3). PMID: 14871849
Highly Cited.
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
Justin Kline, Long Zhang, +2 authors, Thomas F Gajewski.
J Immunol, 2012 Feb 09; 188(6). PMID: 22312128    Free PMC article.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Amy E Moran, Magdalena Kovacsovics-Bankowski, Andrew D Weinberg.
Curr Opin Immunol, 2013 Feb 19; 25(2). PMID: 23414607    Free PMC article.
Transient T cell depletion causes regression of melanoma metastases.
Mary Ann Rasku, Amy L Clem, +8 authors, Jason Chesney.
J Transl Med, 2008 Mar 13; 6. PMID: 18334033    Free PMC article.
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Holly K Koblish, Michael J Hansbury, +11 authors, Jordan S Fridman.
Mol Cancer Ther, 2010 Feb 04; 9(2). PMID: 20124451
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, +3 authors, Nagahiro Minato.
Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188    Free PMC article.
Highly Cited.
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
Thomas F Gajewski, Jamila Louahed, Vincent G Brichard.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693853
Highly Cited. Review.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, +5 authors, J A Bluestone.
Immunity, 1994 Aug 01; 1(5). PMID: 7882171
Highly Cited.
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, +2 authors, George Coukos.
Gynecol Oncol, 2011 Nov 02; 124(2). PMID: 22040834    Free PMC article.
Highly Cited.
Combination antibody-based cancer immunotherapy.
Kazuyoshi Takeda, Ko Okumura, Mark J Smyth.
Cancer Sci, 2007 Jun 15; 98(9). PMID: 17559424
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Jedd D Wolchok, F Stephen Hodi, +9 authors, Alan J Korman.
Ann N Y Acad Sci, 2013 Jun 19; 1291. PMID: 23772560    Free PMC article.
Highly Cited. Review.
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Carmine Carpenito, Michael C Milone, +11 authors, Carl H June.
Proc Natl Acad Sci U S A, 2009 Feb 13; 106(9). PMID: 19211796    Free PMC article.
Highly Cited.
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
Andrew J Rech, Robert H Vonderheide.
Ann N Y Acad Sci, 2009 Sep 23; 1174. PMID: 19769742
Highly Cited. Review.
Reversal of the TCR stop signal by CTLA-4.
Helga Schneider, Jos Downey, +7 authors, Christopher E Rudd.
Science, 2006 Aug 26; 313(5795). PMID: 16931720
Highly Cited.
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Xiangdong Liu, Niu Shin, +19 authors, Peggy A Scherle.
Blood, 2010 Mar 04; 115(17). PMID: 20197554
Highly Cited.
Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Ignacio Melero, Daniel Hirschhorn-Cymerman, +2 authors, Jedd D Wolchok.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460535    Free PMC article.
Highly Cited.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Jaikumar Duraiswamy, Karen M Kaluza, Gordon J Freeman, George Coukos.
Cancer Res, 2013 May 02; 73(12). PMID: 23633484    Free PMC article.
Highly Cited.
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
Liza B John, Christel Devaud, +7 authors, Phillip K Darcy.
Clin Cancer Res, 2013 Jul 23; 19(20). PMID: 23873688
Highly Cited.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.
Maria Libera Ascierto, Michael O Idowu, +13 authors, Masoud H Manjili.
J Transl Med, 2013 Jun 14; 11. PMID: 23758773    Free PMC article.
The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon.
Nat Rev Cancer, 2012 Mar 16; 12(4). PMID: 22419253
Highly Cited. Review.
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
M F Krummel, J P Allison.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676074    Free PMC article.
Highly Cited.
Immunomodulatory cytokines as therapeutic agents for melanoma.
Courtney Nicholas, Gregory B Lesinski.
Immunotherapy, 2011 May 11; 3(5). PMID: 21554095    Free PMC article.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, +18 authors, Dario A A Vignali.
Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141    Free PMC article.
Highly Cited.
The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches.
Cornelia Halin, M Lucila Scimone, +6 authors, Ulrich H von Andrian.
Blood, 2005 May 05; 106(4). PMID: 15870184    Free PMC article.
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Steven A Rosenberg, Mark E Dudley.
Proc Natl Acad Sci U S A, 2004 Sep 24; 101 Suppl 2. PMID: 15381769    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Christopher J Nirschl, Charles G Drake.
Clin Cancer Res, 2013 Jul 23; 19(18). PMID: 23868869    Free PMC article.
Highly Cited. Review.
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Fumiya Hirano, Katsumi Kaneko, +9 authors, Lieping Chen.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705911
Highly Cited.
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Stefani Spranger, Robbert M Spaapen, +4 authors, Thomas F Gajewski.
Sci Transl Med, 2013 Aug 30; 5(200). PMID: 23986400    Free PMC article.
Highly Cited.
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood.
Camilla Jandus, Gilles Bioley, Daniel E Speiser, Pedro Romero.
Cancer Immunol Immunother, 2008 Apr 17; 57(12). PMID: 18414854
Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer.
Yu-Hsin Lin, Jan Friederichs, +14 authors, Anthony E Reeve.
Clin Cancer Res, 2007 Jan 27; 13(2 Pt 1). PMID: 17255271
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
Catherine Uyttenhove, Luc Pilotte, +5 authors, Benoît J Van den Eynde.
Nat Med, 2003 Sep 23; 9(10). PMID: 14502282
Highly Cited.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
Paolo A Ascierto, Antonio M Grimaldi, +32 authors, Magdalena Thurin.
J Transl Med, 2014 Oct 29; 12. PMID: 25348889    Free PMC article.
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Seng-Ryong Woo, Mercedes B Fuertes, +9 authors, Thomas F Gajewski.
Immunity, 2014 Dec 18; 41(5). PMID: 25517615    Free PMC article.
Highly Cited.
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.
Morganna Freeman-Keller, Jeffrey S Weber.
Ther Adv Med Oncol, 2015 Jan 02; 7(1). PMID: 25553080    Free PMC article.
Tryptophan-degrading enzymes in tumoral immune resistance.
Nicolas van Baren, Benoît J Van den Eynde.
Front Immunol, 2015 Feb 19; 6. PMID: 25691885    Free PMC article.
Highly Cited. Review.
Immune therapies in non-muscle invasive bladder cancer.
Philip L Ho, Stephen B Williams, Ashish M Kamat.
Curr Treat Options Oncol, 2015 Mar 12; 16(2). PMID: 25757877
The STING pathway and the T cell-inflamed tumor microenvironment.
Seng-Ryong Woo, Leticia Corrales, Thomas F Gajewski.
Trends Immunol, 2015 Mar 12; 36(4). PMID: 25758021    Free PMC article.
Highly Cited. Review.
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
Fabienne McClanahan, Bola Hanna, +4 authors, Martina Seiffert.
Blood, 2015 Mar 25; 126(2). PMID: 25800048    Free PMC article.
Highly Cited.
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
Katy K Tsai, Adil I Daud.
Drugs, 2015 Mar 25; 75(6). PMID: 25802230
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Jun Liu, Ying Yuan, +8 authors, Li Wang.
Proc Natl Acad Sci U S A, 2015 May 13; 112(21). PMID: 25964334    Free PMC article.
Highly Cited.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski.
Nature, 2015 May 15; 523(7559). PMID: 25970248
Highly Cited.
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
Katherine A Murphy, Britnie R James, +3 authors, Thomas S Griffith.
Hum Vaccin Immunother, 2015 May 23; 11(7). PMID: 25996049    Free PMC article.
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.
N C Hait, D Avni, +10 authors, S Spiegel.
Oncogenesis, 2015 Jun 09; 4. PMID: 26053034    Free PMC article.
Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.
Nathalie Vigneron, Nicolas van Baren, Benoît J Van den Eynde.
Oncoimmunology, 2015 Jul 15; 4(5). PMID: 26155395    Free PMC article.
Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth.
Sheila N Ganti, Tina C Albershardt, Brian M Iritani, Alanna Ruddell.
Sci Rep, 2015 Jul 21; 5. PMID: 26193241    Free PMC article.
Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.
Aliyah M Weinstein, Walter J Storkus.
Adv Cancer Res, 2015 Jul 29; 128. PMID: 26216634    Free PMC article.
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Thomas F Gajewski.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320069    Free PMC article.
Highly Cited. Review.
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Chih-Hao Chang, Jing Qiu, +11 authors, Erika L Pearce.
Cell, 2015 Sep 01; 162(6). PMID: 26321679    Free PMC article.
Highly Cited.
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.
Giorgio Parmiani, Cristina Maccalli, Michele Maio.
Vaccines (Basel), 2015 Sep 08; 3(2). PMID: 26343195    Free PMC article.
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion.
Stefani Spranger, Thomas F Gajewski.
J Immunother Cancer, 2015 Sep 18; 3. PMID: 26380088    Free PMC article.
Immunotherapy and tumor microenvironment.
Haidong Tang, Jian Qiao, Yang-Xin Fu.
Cancer Lett, 2015 Oct 20; 370(1). PMID: 26477683    Free PMC article.
Highly Cited. Review.
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
Jennifer Kleponis, Richard Skelton, Lei Zheng.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487965    Free PMC article.
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Lijie Zhai, Stefani Spranger, +4 authors, Derek A Wainwright.
Clin Cancer Res, 2015 Nov 01; 21(24). PMID: 26519060    Free PMC article.
Highly Cited. Review.
Immune suppressive mechanisms in the tumor microenvironment.
David H Munn, Vincenzo Bronte.
Curr Opin Immunol, 2015 Nov 27; 39. PMID: 26609943    Free PMC article.
Highly Cited. Review.
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
Yong Wha Moon, Joud Hajjar, Patrick Hwu, Aung Naing.
J Immunother Cancer, 2015 Dec 18; 3. PMID: 26674411    Free PMC article.
Highly Cited. Review.
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.
Pan Pantziarka, Vidula Sukhatme, +2 authors, Vikas P Sukhatme.
Ecancermedicalscience, 2016 Jan 30; 10. PMID: 26823679    Free PMC article.
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
David H Munn, Andrew L Mellor.
Trends Immunol, 2016 Feb 04; 37(3). PMID: 26839260    Free PMC article.
Highly Cited. Review.
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Stefani Spranger, Ayelet Sivan, Leticia Corrales, Thomas F Gajewski.
Adv Immunol, 2016 Mar 01; 130. PMID: 26923000    Free PMC article.
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
Haidong Tang, Yang Wang, +6 authors, Yang-Xin Fu.
Cancer Cell, 2016 Mar 16; 29(3). PMID: 26977880    Free PMC article.
Highly Cited.
Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Arta M Monjazeb, Michael S Kent, +13 authors, William J Murphy.
Clin Cancer Res, 2016 Mar 17; 22(17). PMID: 26979392    Free PMC article.
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Stefani Spranger.
Int Immunol, 2016 Mar 19; 28(8). PMID: 26989092    Free PMC article.
Highly Cited. Review.
A phase I study of indoximod in patients with advanced malignancies.
Hatem H Soliman, Susan E Minton, +13 authors, Scott J Antonia.
Oncotarget, 2016 Mar 24; 7(16). PMID: 27008709    Free PMC article.
Highly Cited.
The emerging role of FTY720 (Fingolimod) in cancer treatment.
Christopher White, Heba Alshaker, +2 authors, Dmitri Pchejetski.
Oncotarget, 2016 Apr 02; 7(17). PMID: 27036015    Free PMC article.
Reversing T-cell Dysfunction and Exhaustion in Cancer.
Hassane M Zarour.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084739    Free PMC article.
Highly Cited. Review.
Targetless T cells in cancer immunotherapy.
Per Thor Straten, Federico Garrido.
J Immunother Cancer, 2016 Apr 21; 4. PMID: 27096099    Free PMC article.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon, Juliana Idoyaga, +19 authors, Miriam Merad.
Immunity, 2016 Apr 21; 44(4). PMID: 27096321    Free PMC article.
Highly Cited.
Tumor-intrinsic oncogene pathways mediating immune avoidance.
Stefani Spranger, Thomas F Gajewski.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141343    Free PMC article.
Highly Cited. Review.
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Caroline Jochems, Massimo Fantini, +13 authors, Kwong Y Tsang.
Oncotarget, 2016 Oct 23; 7(25). PMID: 27192116    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Nicole C Smits, Tiffany A Coupet, Claire Godbersen, Charles L Sentman.
Expert Opin Biol Ther, 2016 Jun 02; 16(9). PMID: 27248342    Free PMC article.
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Zhenhua Ren, Jingya Guo, +7 authors, Yang-Xin Fu.
Clin Cancer Res, 2016 Jun 30; 23(1). PMID: 27354469    Free PMC article.
The host STING pathway at the interface of cancer and immunity.
Leticia Corrales, Sarah M McWhirter, Thomas W Dubensky, Thomas F Gajewski.
J Clin Invest, 2016 Jul 02; 126(7). PMID: 27367184    Free PMC article.
Highly Cited. Review.
Metastatic melanoma and immunotherapy.
Benjamin Herzberg, David E Fisher.
Clin Immunol, 2016 Jul 20; 172. PMID: 27430520    Free PMC article.
Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.
Josephine F Trott, Jeffrey Kim, +11 authors, Robert H Weiss.
Oncotarget, 2016 Aug 31; 7(41). PMID: 27572319    Free PMC article.
Exercise: A new role for an old tool.
Manja Idorn, Per Thor Straten.
Mol Cell Oncol, 2016 Sep 22; 3(4). PMID: 27652317    Free PMC article.
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Cara C Schafer, Yong Wang, +6 authors, Jessy S Deshane.
Oncotarget, 2016 Oct 06; 7(46). PMID: 27705910    Free PMC article.
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Shu Wang, Jose Campos, +5 authors, Cristiana Guiducci.
Proc Natl Acad Sci U S A, 2016 Nov 02; 113(46). PMID: 27799536    Free PMC article.
Highly Cited.
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.
Yichao Chen, Rui Xia, +10 authors, Song Li.
Nat Commun, 2016 Nov 08; 7. PMID: 27819653    Free PMC article.
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Wei Xue, Victoria A Brentville, +4 authors, Lindy G Durrant.
Oncotarget, 2016 Nov 09; 7(50). PMID: 27825115    Free PMC article.
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
Stefani Spranger, Jason J Luke, +6 authors, Thomas F Gajewski.
Proc Natl Acad Sci U S A, 2016 Nov 12; 113(48). PMID: 27837020    Free PMC article.
Highly Cited.
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Ludmila Danilova, Hao Wang, +9 authors, Janis M Taube.
Proc Natl Acad Sci U S A, 2016 Nov 12; 113(48). PMID: 27837027    Free PMC article.
Highly Cited.
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Maarten Swart, Inge Verbrugge, Joost B Beltman.
Front Oncol, 2016 Nov 17; 6. PMID: 27847783    Free PMC article.
Highly Cited. Review.
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
B Bonavida, S Chouaib.
Ann Oncol, 2016 Nov 20; 28(3). PMID: 27864216    Free PMC article.
Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3- Dioxygenase Mediated-antitumor Efficiency.
Kuan-Ting Liu, Yao-Hua Liu, +3 authors, Po-Lin Kuo.
Mol Ther Nucleic Acids, 2016 Dec 07; 5(12). PMID: 27922590    Free PMC article.
Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Sinnie Sin Man Ng, Bethany A Nagy, +6 authors, George N Pavlakis.
Clin Cancer Res, 2016 Dec 18; 23(11). PMID: 27986749    Free PMC article.
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Gregory L Beatty, Peter J O'Dwyer, +8 authors, Thomas F Gajewski.
Clin Cancer Res, 2017 Jan 06; 23(13). PMID: 28053021    Free PMC article.
Highly Cited.
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.
Kenji Chamoto, Partha S Chowdhury, +4 authors, Tasuku Honjo.
Proc Natl Acad Sci U S A, 2017 Jan 18; 114(5). PMID: 28096382    Free PMC article.
Highly Cited.
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Matthew H Spitzer, Yaron Carmi, +10 authors, Edgar G Engleman.
Cell, 2017 Jan 24; 168(3). PMID: 28111070    Free PMC article.
Highly Cited.
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114250    Free PMC article.
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
Jason B Williams, Brendan L Horton, +3 authors, Thomas F Gajewski.
J Exp Med, 2017 Jan 25; 214(2). PMID: 28115575    Free PMC article.
Highly Cited.
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.
Nina Eissler, Yumeng Mao, +5 authors, Per Kogner.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123870    Free PMC article.
Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.
Paul M Tyler, Mariah M Servos, +6 authors, Stephanie K Dougan.
Mol Cancer Ther, 2017 Feb 06; 16(3). PMID: 28148714    Free PMC article.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Targeting neoantigens to augment antitumour immunity.
Mark Yarchoan, Burles A Johnson, +2 authors, Elizabeth M Jaffee.
Nat Rev Cancer, 2017 Feb 25; 17(4). PMID: 28233802    Free PMC article.
Highly Cited. Review.
Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Mohanad H Nada, Hong Wang, +2 authors, Craig T Morita.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239463    Free PMC article.
Exercise and cancer: from "healthy" to "therapeutic"?
Manja Idorn, Per Thor Straten.
Cancer Immunol Immunother, 2017 Mar 23; 66(5). PMID: 28324125    Free PMC article.
Systematic evaluation of immune regulation and modulation.
David F Stroncek, Lisa H Butterfield, +12 authors, Barbara Seliger.
J Immunother Cancer, 2017 Mar 24; 5. PMID: 28331613    Free PMC article.
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
Stefan Langhammer, Joachim Scheerer.
Oncotarget, 2017 Apr 14; 8(26). PMID: 28402937    Free PMC article.
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Stefani Spranger, Daisy Dai, Brendan Horton, Thomas F Gajewski.
Cancer Cell, 2017 May 10; 31(5). PMID: 28486109    Free PMC article.
Highly Cited.
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Eddy W Yue, Richard Sparks, +23 authors, Andrew P Combs.
ACS Med Chem Lett, 2017 May 20; 8(5). PMID: 28523098    Free PMC article.
Highly Cited.
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Roberta Mazzone, Clemens Zwergel, Antonello Mai, Sergio Valente.
Clin Epigenetics, 2017 Jun 03; 9. PMID: 28572863    Free PMC article.
Highly Cited. Review.
Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
Yoshimasa Tanaka, Masashi Iwasaki, +7 authors, Masakazu Toi.
Sci Rep, 2017 Jul 22; 7(1). PMID: 28729550    Free PMC article.
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Janet L Martin, Sohel M Julovi, +3 authors, Robert C Baxter.
Breast Cancer Res, 2017 Aug 06; 19(1). PMID: 28778177    Free PMC article.
TIM-4 Identifies IFN-γ-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.
Qing Ding, Kanishka Mohib, Vijay K Kuchroo, David M Rothstein.
J Immunol, 2017 Aug 30; 199(7). PMID: 28848066    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Yuki Muroyama, Thomas R Nirschl, +14 authors, Charles G Drake.
Cancer Immunol Res, 2017 Oct 04; 5(11). PMID: 28970196    Free PMC article.
Highly Cited.
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.
Mariana Aris, José Mordoh, María Marcela Barrio.
Front Immunol, 2017 Oct 04; 8. PMID: 28970830    Free PMC article.
The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken.
Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585
Highly Cited. Review.
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
Brendan L Horton, Jason B Williams, +2 authors, Thomas F Gajewski.
Cancer Immunol Res, 2017 Nov 04; 6(1). PMID: 29097422    Free PMC article.
Heterogeneity of colon cancer: from bench to bedside.
Marco C Merlano, Cristina Granetto, +2 authors, Ornella Garrone.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209524    Free PMC article.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Discovery of IDO1 Inhibitors: From Bench to Bedside.
George C Prendergast, William P Malachowski, James B DuHadaway, Alexander J Muller.
Cancer Res, 2017 Dec 17; 77(24). PMID: 29247038    Free PMC article.
Highly Cited. Review.
Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Theodore S Johnson, Tracy Mcgaha, David H Munn.
Adv Exp Med Biol, 2017 Dec 25; 1036. PMID: 29275467    Free PMC article.
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Diwakar Davar, Nathan Bahary.
Target Oncol, 2018 Jan 06; 13(2). PMID: 29302770
Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Zhengping Hu, Liang Ye, +2 authors, Tao Xi.
Sci Rep, 2018 Jan 11; 8(1). PMID: 29317734    Free PMC article.
Impact of oncogenic pathways on evasion of antitumour immune responses.
Stefani Spranger, Thomas F Gajewski.
Nat Rev Cancer, 2018 Jan 13; 18(3). PMID: 29326431    Free PMC article.
Highly Cited. Review.
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Haidong Tang, Yong Liang, +18 authors, Yang-Xin Fu.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337303    Free PMC article.
Highly Cited.
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Charlotte E Ariyan, Mary Sue Brady, +19 authors, James P Allison.
Cancer Immunol Res, 2018 Jan 18; 6(2). PMID: 29339377    Free PMC article.
IDO1 in cancer: a Gemini of immune checkpoints.
Lijie Zhai, Erik Ladomersky, +5 authors, Derek A Wainwright.
Cell Mol Immunol, 2018 Jan 30; 15(5). PMID: 29375124    Free PMC article.
Highly Cited. Review.
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Priya Srinivasan, Xiaofang Wu, +2 authors, Anthony D Sandler.
PLoS Med, 2018 Jan 30; 15(1). PMID: 29377881    Free PMC article.
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
David Taggart, Tereza Andreou, +7 authors, Mihaela Lorger.
Proc Natl Acad Sci U S A, 2018 Feb 02; 115(7). PMID: 29386395    Free PMC article.
Highly Cited.
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.
George C Prendergast, Arpita Mondal, +2 authors, Alexander J Muller.
Trends Cancer, 2018 Feb 08; 4(1). PMID: 29413421    Free PMC article.
Highly Cited. Review.
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
George C Prendergast, William J Malachowski, +2 authors, Alexander J Muller.
Int Rev Cell Mol Biol, 2018 Feb 08; 336. PMID: 29413890    Free PMC article.
Highly Cited. Review.
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.
Olivier Belzile, Xianming Huang, +4 authors, Bruce D Freimark.
Immunotargets Ther, 2018 Feb 09; 7. PMID: 29417044    Free PMC article.
Improvement of Antitumor Therapies Based on Vaccines and Immune-Checkpoint Inhibitors by Counteracting Tumor-Immunostimulation.
Paula Chiarella, Mónica Vermeulen, +6 authors, Richmond T Prehn.
Front Oncol, 2018 Feb 13; 8. PMID: 29435437    Free PMC article.
High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.
Andreas Seeber, Gerald Klinglmair, +8 authors, Renate Pichler.
Cancer Sci, 2018 Mar 03; 109(5). PMID: 29498788    Free PMC article.
MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells.
Fen Huang, Bo Wang, +3 authors, Yanda Lu.
Oncol Lett, 2018 Mar 20; 15(4). PMID: 29552119    Free PMC article.
Current status and perspectives in immunotherapy for metastatic melanoma.
Riccardo Marconcini, Francesco Spagnolo, +13 authors, Italian Melanoma Intergroup (IMI).
Oncotarget, 2018 Mar 20; 9(15). PMID: 29552325    Free PMC article.
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Jeremy M Grenier, Stephen T Yeung, Kamal M Khanna.
Front Immunol, 2018 Apr 07; 9. PMID: 29623082    Free PMC article.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.
Marka R Crittenden, Lauren Zebertavage, +7 authors, Michael J Gough.
Sci Rep, 2018 May 05; 8(1). PMID: 29725089    Free PMC article.
Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).
Zhonghua Pei, Rohan Mendonca, +13 authors, Benjamin D Sellers.
ACS Med Chem Lett, 2018 May 26; 9(5). PMID: 29795752    Free PMC article.
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Rikke B Holmgaard, David A Schaer, +14 authors, Kyla E Driscoll.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866156    Free PMC article.
Highly Cited.
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Asha Nayak-Kapoor, Zhonglin Hao, +18 authors, Samir N Khleif.
J Immunother Cancer, 2018 Jun 21; 6(1). PMID: 29921320    Free PMC article.
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Zachary J Brown, Su Jong Yu, +7 authors, Tim F Greten.
Cancer Immunol Immunother, 2018 Jul 01; 67(8). PMID: 29959458    Free PMC article.
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.
Michael Flynn, Lisa Pickering, James Larkin, Samra Turajlic.
Ther Adv Med Oncol, 2018 Jul 07; 10. PMID: 29977349    Free PMC article.
IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
Bhalchandra Mirlekar, Daniel Michaud, +2 authors, Yuliya Pylayeva-Gupta.
Cancer Immunol Res, 2018 Jul 08; 6(9). PMID: 29980536    Free PMC article.
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Kavitha Gowrishankar, Lucy Birtwistle, Kenneth Micklethwaite.
Mamm Genome, 2018 Jul 11; 29(11-12). PMID: 29987406
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Todd A Triplett, Kendra C Garrison, +23 authors, George Georgiou.
Nat Biotechnol, 2018 Jul 17; 36(8). PMID: 30010674    Free PMC article.
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Michael Flynn, Kate Young, David Cunningham, Naureen Starling.
Ther Adv Med Oncol, 2018 Jul 24; 10. PMID: 30034550    Free PMC article.
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance.
Young-Jun Park, Da-Sol Kuen, Yeonseok Chung.
Exp Mol Med, 2018 Aug 24; 50(8). PMID: 30135516    Free PMC article.
Highly Cited. Review.
Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy.
Barbara Wegiel, Marta Vuerich, Saeed Daneshmandi, Pankaj Seth.
Front Oncol, 2018 Aug 29; 8. PMID: 30151352    Free PMC article.
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
Jason M Redman, Seth M Steinberg, James L Gulley.
J Immunother Cancer, 2018 Sep 20; 6(1). PMID: 30227893    Free PMC article.
Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.
Huseyin Atakan Ekiz, Shu-Chin Alicia Lai, +3 authors, Alana L Welm.
Oncoimmunology, 2018 Sep 20; 7(9). PMID: 30228950    Free PMC article.
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
Tara C Mitchell, Omid Hamid, +11 authors, Thomas F Gajewski.
J Clin Oncol, 2018 Sep 29; 36(32). PMID: 30265610    Free PMC article.
Highly Cited.
Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.
Catherine T Flores, Tyler J Wildes, +4 authors, Duane A Mitchell.
Nat Commun, 2018 Oct 20; 9(1). PMID: 30333482    Free PMC article.
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
Lu Xu, Yang Zhang, +13 authors, Han Liu.
J Exp Clin Cancer Res, 2018 Oct 31; 37(1). PMID: 30373602    Free PMC article.
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression.
Elena Gianchecchi, Alessandra Fierabracci.
Front Immunol, 2018 Nov 06; 9. PMID: 30386337    Free PMC article.
Highly Cited. Review.
The Identification of Immunological Biomarkers in Kidney Cancers.
Antonio Lopez-Beltran, Vanessa Henriques, +7 authors, Rodolfo Montironi.
Front Oncol, 2018 Nov 20; 8. PMID: 30450335    Free PMC article.
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Spencer C Wei, Nana-Ama A S Anang, +8 authors, James P Allison.
Proc Natl Acad Sci U S A, 2019 Oct 23; 116(45). PMID: 31636208    Free PMC article.
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile.
Rosa De Groot, Marleen M Van Loenen, +13 authors, Monika C Wolkers.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646094    Free PMC article.
Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or Supporting Act in the Tuberculosis and HIV Pas-de-Deux?
Clement Gascua Adu-Gyamfi, Dana Savulescu, Jaya Anna George, Melinda Shelley Suchard.
Front Cell Infect Microbiol, 2019 Nov 19; 9. PMID: 31737575    Free PMC article.
CTLA-4 correlates with immune and clinical characteristics of glioma.
Fangkun Liu, Jing Huang, +3 authors, Zhixiong Liu.
Cancer Cell Int, 2020 Jan 09; 20. PMID: 31911758    Free PMC article.
The therapeutic potential of targeting tryptophan catabolism in cancer.
Christiane A Opitz, Luis F Somarribas Patterson, +4 authors, Saskia Trump.
Br J Cancer, 2019 Dec 11; 122(1). PMID: 31819194    Free PMC article.
Tumor immune response and immunotherapy in gastric cancer.
Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee.
J Pathol Transl Med, 2019 Nov 02; 54(1). PMID: 31674166    Free PMC article.
Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.
Pankaj Kumar, Amit Kumar, +2 authors, William Bishai.
Immunotherapy, 2019 Jul 31; 11(13). PMID: 31361167    Free PMC article.
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Gayathri Vijayakumar, Stephen McCroskery, Peter Palese.
J Virol, 2019 Nov 07; 94(3). PMID: 31694938    Free PMC article.
The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression.
Jun-Bao Liu, Dan Chen, +2 authors, Chen Yu.
Front Pharmacol, 2020 Feb 11; 10. PMID: 32038231    Free PMC article.
Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations.
Xinyu Liu, Yiwen Zhang, +7 authors, Hubing Shi.
Front Mol Biosci, 2020 Feb 13; 6. PMID: 32047753    Free PMC article.
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Xiu-Xiu Wang, Si-Yu Sun, +3 authors, Ya-Qun Xing.
Medchemcomm, 2020 Feb 15; 10(10). PMID: 32055299    Free PMC article.
Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
Malek Kreidieh, Deborah Mukherji, Sally Temraz, Ali Shamseddine.
Biomed Res Int, 2020 Feb 25; 2020. PMID: 32090113    Free PMC article.
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Dayana Herrera-Rios, Sadaf S Mughal, +13 authors, Iris Helfrich.
Front Immunol, 2020 Mar 03; 11. PMID: 32117271    Free PMC article.
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.
Sonja C S Simon, Xiaoying Hu, +7 authors, Viktor Umansky.
Oncoimmunology, 2020 Mar 03; 9(1). PMID: 32117594    Free PMC article.
A tumor-targeted immune checkpoint blocker.
Yuhan Zhang, Changming Fang, +9 authors, Feng Wang.
Proc Natl Acad Sci U S A, 2019 Jul 25; 116(32). PMID: 31332018    Free PMC article.
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Mohammad Rashidian, Martin W LaFleur, +13 authors, Hidde L Ploegh.
Proc Natl Acad Sci U S A, 2019 Aug 04; 116(34). PMID: 31375632    Free PMC article.
Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.
Soudabeh Rad Pour, Hiromasa Morikawa, +11 authors, Jesper Tegnér.
Sci Rep, 2019 Aug 23; 9(1). PMID: 31434983    Free PMC article.
B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer.
Bhalchandra Mirlekar, Daniel Michaud, +14 authors, Yuliya Pylayeva-Gupta.
Cancer Immunol Res, 2020 Feb 07; 8(3). PMID: 32024640    Free PMC article.
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han.
J Hematol Oncol, 2018 Feb 28; 11(1). PMID: 29482595    Free PMC article.
Highly Cited. Review.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Christopher S Garris, Sean P Arlauckas, +20 authors, Mikael J Pittet.
Immunity, 2018 Dec 16; 49(6). PMID: 30552023    Free PMC article.
Highly Cited.
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.
Mayanne M T Zhu, Amanda R Dancsok, Torsten O Nielsen.
Curr Oncol Rep, 2019 Jan 20; 21(1). PMID: 30659394
Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.
Bradley D Shields, Brian Koss, +8 authors, Alan J Tackett.
Cancer Res, 2019 Jan 25; 79(6). PMID: 30674537    Free PMC article.
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
Geoffrey T Gibney, Omid Hamid, +10 authors, Jeffrey S Weber.
J Immunother Cancer, 2019 Mar 22; 7(1). PMID: 30894212    Free PMC article.
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Melvyn T Chow, Aleksandra J Ozga, +6 authors, Andrew D Luster.
Immunity, 2019 May 18; 50(6). PMID: 31097342    Free PMC article.
Highly Cited.
Mechanisms of Resistance to PD-1 Checkpoint Blockade.
Justin C Moser, Siwen Hu-Lieskovan.
Drugs, 2020 Feb 26; 80(5). PMID: 32096021
New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
Yang Wang, Ning Zhao, +7 authors, Xiubao Ren.
Eur J Nucl Med Mol Imaging, 2019 Sep 11; 47(5). PMID: 31502013
Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
Baosheng Chen, David M Alvarado, +5 authors, Matthew A Ciorba.
Cancer Immunol Res, 2020 Mar 05; 8(4). PMID: 32127391    Free PMC article.
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Duaa O Khair, Heather J Bax, +22 authors, Sophia N Karagiannis.
Front Immunol, 2019 Apr 04; 10. PMID: 30941125    Free PMC article.
Highly Cited. Review.
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.
Jared M Newton, Aurelie Hanoteau, +11 authors, Andrew G Sikora.
J Immunother Cancer, 2019 Aug 15; 7(1). PMID: 31409394    Free PMC article.
Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-an Industry Perspective.
Jun Xu, Robert Saklatvala, +2 authors, Adam Procopio.
Adv Sci (Weinh), 2020 Apr 25; 7(8). PMID: 32328428    Free PMC article.
Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Hong Qiu, Patrick M Zmina, +2 authors, Barbara Bedogni.
Cancer Lett, 2018 Jul 24; 434. PMID: 30036609    Free PMC article.
Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy.
Michael J Gough, Shay Sharon, Marka R Crittenden, Kristina H Young.
Semin Radiat Oncol, 2020 May 10; 30(2). PMID: 32381295    Free PMC article.
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Aohan Hou, Kaiyu Hou, +2 authors, Wanling Chen.
Front Immunol, 2020 Jun 09; 11. PMID: 32508809    Free PMC article.
Metabolic Traits in Cutaneous Melanoma.
Monica Neagu.
Front Oncol, 2020 Jun 09; 10. PMID: 32509589    Free PMC article.
Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.
Wangyang Tu, Fanglong Yang, +12 authors, Weikang Tao.
ACS Med Chem Lett, 2019 Jun 22; 10(6). PMID: 31223453    Free PMC article.
Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model.
Mary-Ann N Jallad, Abdo R Jurjus, Elias A Rahal, Alexander M Abdelnoor.
Front Oncol, 2020 Jul 01; 10. PMID: 32596146    Free PMC article.
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses.
Souvik Dey, Erika Sutanto-Ward, +10 authors, Alexander J Muller.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690770    Free PMC article.
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Qingyang Lei, Dan Wang, +2 authors, Yi Zhang.
Front Cell Dev Biol, 2020 Aug 15; 8. PMID: 32793604    Free PMC article.
Myeloid-Derived Suppressor Cells in Colorectal Cancer.
Izabela Sieminska, Jarek Baran.
Front Immunol, 2020 Aug 28; 11. PMID: 32849517    Free PMC article.
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Shin Foong Ngiow, Arabella Young.
Front Immunol, 2020 Aug 28; 11. PMID: 32849557    Free PMC article.
Progress in Neoantigen Targeted Cancer Immunotherapies.
Xue-Jiao Han, Xue-Lei Ma, +3 authors, Xia-Wei Wei.
Front Cell Dev Biol, 2020 Aug 28; 8. PMID: 32850843    Free PMC article.
Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.
Hui Yi Chew, Riccardo Dolcetti, Fiona Simpson.
Br J Clin Pharmacol, 2020 May 07; 86(9). PMID: 32372470    Free PMC article.
Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy.
Ava Vila-Leahey, Alecia MacKay, +3 authors, Marianne M Stanford.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923145    Free PMC article.
[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Xiaoxiao Peng, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591101    Free PMC article.
1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function.
Huihan Ma, Qian Qin, Jiaqing Mi, Qinmei Feng.
BMC Pharmacol Toxicol, 2020 Sep 12; 21(1). PMID: 32912307    Free PMC article.
Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy.
Mona Yazdani, Mahdi Hatamipour, +6 authors, Ali Badiee.
Iran J Basic Med Sci, 2020 Sep 22; 23(8). PMID: 32952954    Free PMC article.
Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells.
Fiamma Salerno, Aurelie Guislain, +3 authors, Monika C Wolkers.
Oncoimmunology, 2019 Feb 05; 8(2). PMID: 30713785    Free PMC article.
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
Shweta Joshi, Donald L Durden.
J Oncol, 2019 Mar 12; 2019. PMID: 30853982    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy.
Brendon J Coventry.
Ther Adv Vaccines Immunother, 2019 Aug 16; 7. PMID: 31414074    Free PMC article.
Tissue Site and the Cancer Immunity Cycle.
Brendan L Horton, Tim B Fessenden, Stefani Spranger.
Trends Cancer, 2019 Nov 11; 5(10). PMID: 31706507    Free PMC article.
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer.
Matthew D Hellmann, Scott Gettinger, +8 authors, Rebecca S Heist.
Int J Cancer, 2020 Mar 07; 147(7). PMID: 32141617    Free PMC article.
IDO Expression in Cancer: Different Compartment, Different Functionality?
Annabel Meireson, Michael Devos, Lieve Brochez.
Front Immunol, 2020 Oct 20; 11. PMID: 33072086    Free PMC article.
Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
Shigemune Bekki, Satoru Hashimoto, +11 authors, Hiroshi Yatsuhashi.
PLoS One, 2020 Oct 22; 15(10). PMID: 33085694    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone.
Yang Lin, Heyanhao Zhang, +2 authors, Jun Chang.
Molecules, 2020 Oct 04; 25(19). PMID: 33007982    Free PMC article.
EZH2 as a Regulator of CD8+ T Cell Fate and Function.
Christopher J Stairiker, Graham D Thomas, Shahram Salek-Ardakani.
Front Immunol, 2020 Oct 30; 11. PMID: 33117406    Free PMC article.
The Influence of Tumor Microenvironment on Immune Escape of Melanoma.
Aleksandra Simiczyjew, Ewelina Dratkiewicz, +3 authors, Dorota Nowak.
Int J Mol Sci, 2020 Nov 12; 21(21). PMID: 33171792    Free PMC article.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models.
Tristan Rupp, Océane Pelouin, +3 authors, Vincent Castagné.
Transl Oncol, 2020 Nov 07; 14(1). PMID: 33157518    Free PMC article.
Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Adekunle Odunsi, A J Robert McGray, +5 authors, Ruea-Yea Huang.
J Immunother Cancer, 2020 Nov 13; 8(2). PMID: 33177175    Free PMC article.
The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation Against Cancer.
Sandra Iurescia, Daniela Fioretti, Monica Rinaldi.
Cancers (Basel), 2020 Oct 31; 12(11). PMID: 33121210    Free PMC article.
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Danielle M Lussier, Lauren O'Neill, +7 authors, Joseph N Blattman.
J Immunother, 2015 Mar 10; 38(3). PMID: 25751499    Free PMC article.
Highly Cited.
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer.
Kurt A Schalper, Daniel Carvajal-Hausdorf, +7 authors, David L Rimm.
Clin Cancer Res, 2016 Jul 22; 23(2). PMID: 27440266    Free PMC article.
Highly Cited.
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Thomas F Gajewski, Leticia Corrales, +3 authors, Stefani Spranger.
Adv Exp Med Biol, 2017 Dec 25; 1036. PMID: 29275462    Free PMC article.
Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation.
Xi Xu, Jie Ren, +8 authors, Jinlei Bian.
J Enzyme Inhib Med Chem, 2019 Feb 09; 34(1). PMID: 30734612    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.
Javier Arranz-Nicolás, Miguel Martin-Salgado, +6 authors, Isabel Merida.
J Immunother Cancer, 2020 Nov 29; 8(2). PMID: 33246984    Free PMC article.
Natural Phenolic Acid, Product of the Honey Bee, for the Control of Oxidative Stress, Peritoneal Angiogenesis, and Tumor Growth in Mice.
Nada Oršolić, Martina Kunštić, +2 authors, Daniela Ančić.
Molecules, 2020 Dec 03; 25(23). PMID: 33261130    Free PMC article.
Cell and tissue engineering in lymph nodes for cancer immunotherapy.
Alexander J Najibi, David J Mooney.
Adv Drug Deliv Rev, 2020 Aug 05; 161-162. PMID: 32750376    Free PMC article.
Systematic Review.
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy.
Lydia S Lamb, Hao-Wen Sim, Ann I McCormack.
Front Endocrinol (Lausanne), 2020 Dec 15; 11. PMID: 33312158    Free PMC article.
The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review.
Lanfang Zhang, Mingjuan Zhang, +6 authors, Meiling Gu.
Ann Transl Med, 2020 Dec 15; 8(22). PMID: 33313271    Free PMC article.
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
Amy J Wisdom, Yvonne M Mowery, +22 authors, David G Kirsch.
Nat Commun, 2020 Dec 19; 11(1). PMID: 33335088    Free PMC article.
High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC).
James Monkman, Touraj Taheri, +5 authors, Arutha Kulasinghe.
Cancers (Basel), 2020 Dec 03; 12(12). PMID: 33261133    Free PMC article.
Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review).
Gui-Xian Zhu, Dian Gao, +3 authors, Qiong-Fang Yu.
Mol Med Rep, 2020 Dec 11; 23(2). PMID: 33300082    Free PMC article.
Colon cancer and immunotherapy-can we go beyond microsatellite instability?
Rimini Breakstone.
Transl Gastroenterol Hepatol, 2021 Jan 08; 6. PMID: 33409406    Free PMC article.
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Mengze Lv, Meixia Chen, +13 authors, Zhengfan Jiang.
Cell Res, 2020 Aug 26; 30(11). PMID: 32839553    Free PMC article.
Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.
Bruce D Freimark, Jian Gong, +9 authors, Xianming Huang.
Cancer Immunol Res, 2016 Apr 06; 4(6). PMID: 27045021    Free PMC article.
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.
Jim Middelburg, Kristel Kemper, +3 authors, Thorbald van Hall.
Cancers (Basel), 2021 Jan 21; 13(2). PMID: 33466732    Free PMC article.
IFN-γ and CD38 in Hyperprogressive Cancer Development.
Stefania Angelicola, Francesca Ruzzi, +6 authors, Arianna Palladini.
Cancers (Basel), 2021 Jan 21; 13(2). PMID: 33467713    Free PMC article.
Multi-scale modeling of macrophage-T cell interactions within the tumor microenvironment.
Colin G Cess, Stacey D Finley.
PLoS Comput Biol, 2020 Dec 29; 16(12). PMID: 33362239    Free PMC article.
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Toshihiko Doi, Yutaka Fujiwara, +12 authors, Noboru Yamamoto.
Invest New Drugs, 2020 Jun 22; 39(1). PMID: 32564277
Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Ayse Basak Engin, Atilla Engin.
Adv Exp Med Biol, 2021 Feb 05; 1275. PMID: 33539022
Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
Chao-Yuan Weng, Cheng-Xiang Kao, Te-Sheng Chang, Yen-Hua Huang.
Int J Mol Sci, 2021 Jan 31; 22(3). PMID: 33514004    Free PMC article.
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yu Yao, Heng Liang, +6 authors, Qing Yang.
J Exp Clin Cancer Res, 2021 Feb 10; 40(1). PMID: 33557876    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Heterodimeric IL-15 in Cancer Immunotherapy.
Cristina Bergamaschi, Vasiliki Stravokefalou, +3 authors, George N Pavlakis.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33671252    Free PMC article.
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT.
Nicola Tumino, Anna Laura Di Pace, +3 authors, Lorenzo Moretta.
Front Immunol, 2021 Mar 09; 12. PMID: 33679798    Free PMC article.
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Minah Kim, Petr Tomek.
Front Immunol, 2021 Mar 13; 12. PMID: 33708223    Free PMC article.
[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
Haoyang Li, Jinghui Wang.
Zhongguo Fei Ai Za Zhi, 2021 Jan 29; 24(2). PMID: 33508897    Free PMC article.
Roles and molecular mechanisms of physical exercise in cancer prevention and treatment.
Qiaoyun Wang, Wenli Zhou.
J Sport Health Sci, 2020 Aug 02; 10(2). PMID: 32738520    Free PMC article.
Inotodiol From Inonotus obliquus Chaga Mushroom Induces Atypical Maturation in Dendritic Cells.
Perry Ayn Mayson A Maza, Ji-Hyun Lee, +6 authors, Jong-Young Kwak.
Front Immunol, 2021 Mar 30; 12. PMID: 33777049    Free PMC article.
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.
Guangna Liu, Wei Rui, Xueqiang Zhao, Xin Lin.
Cell Mol Immunol, 2021 Apr 01; 18(5). PMID: 33785843    Free PMC article.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Craig L Slingluff, Hassane M Zarour, +13 authors, Jedd D Wolchok.
Oncoimmunology, 2021 Apr 03; 10(1). PMID: 33796406    Free PMC article.
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Kai Tang, Ya-Hong Wu, Yihui Song, Bin Yu.
J Hematol Oncol, 2021 Apr 23; 14(1). PMID: 33883013    Free PMC article.
Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.
Kyle G Mitchell, Edwin R Parra, +6 authors, MD Anderson Lung Cancer Immune Microenvironment Working Group.
J Thorac Cardiovasc Surg, 2019 Jun 27; 158(3). PMID: 31235357    Free PMC article.
CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade.
Julie Vackova, Ingrid Polakova, Shweta Dilip Johari, Michal Smahel.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33923750    Free PMC article.
Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.
Yalei Zhang, Ye Li, +2 authors, Peng Wang.
Cancer Cell Int, 2021 May 15; 21(1). PMID: 33985527    Free PMC article.
Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
R Zou, Y Wang, +3 authors, S Cui.
Clin Transl Oncol, 2021 May 19; 23(11). PMID: 34002348
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Jie Zhang, Zhujiang Dai, +3 authors, Dong Tang.
Clin Transl Oncol, 2021 Jun 15; 23(12). PMID: 34125407    Free PMC article.
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer.
Yong Jun Lee, Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim.
Mol Cells, 2021 May 19; 44(5). PMID: 34001680    Free PMC article.
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research.
Hrishi Varayathu, Vinu Sarathy, +2 authors, Radheshyam Naik.
Front Oncol, 2021 Jun 15; 11. PMID: 34123767    Free PMC article.
Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Concetta Quintarelli, Antonio Camera, +6 authors, Biagio De Angelis.
Front Immunol, 2021 Jun 25; 12. PMID: 34163465    Free PMC article.
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef Zakharia, Robert R McWilliams, +17 authors, Mohammed Milhem.
J Immunother Cancer, 2021 Jun 13; 9(6). PMID: 34117113    Free PMC article.
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.
Claudia Trojaniello, Jason J Luke, Paolo A Ascierto.
Front Oncol, 2021 Jun 29; 11. PMID: 34178657    Free PMC article.
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection.
Shay Sharon, Jason R Baird, +8 authors, Michael J Gough.
Oncotarget, 2021 Jul 02; 12(13). PMID: 34194619    Free PMC article.
Explant Modeling of the Immune Environment of Head and Neck Cancer.
Shay Sharon, Thomas Duhen, +9 authors, Michael Gough.
Front Oncol, 2021 Jul 06; 11. PMID: 34221953    Free PMC article.
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.
Xiaochen Yang, Wing Lam, +12 authors, Yung-Chi Cheng.
Sci Rep, 2021 Jul 01; 11(1). PMID: 34188068    Free PMC article.
Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers.
Juan C García-Cañaveras, Agustín Lahoz.
Cancers (Basel), 2021 Jul 03; 13(13). PMID: 34203535    Free PMC article.
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
Lizza E L Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295685    Free PMC article.
Genomic and Immunologic Correlates of Indoleamine 2,3-Dioxygenase Pathway Expression in Cancer.
Anshuman Panda, Shridar Ganesan.
Front Genet, 2021 Aug 10; 12. PMID: 34367262    Free PMC article.
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.
Renata Ferrarotto, Diana Bell, +16 authors, Neil D Gross.
Clin Cancer Res, 2020 Apr 10; 26(13). PMID: 32269052    Free PMC article.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
Andrea De Giglio, Alessandro Di Federico, +2 authors, Francesco Gelsomino.
Curr Oncol Rep, 2021 Aug 29; 23(11). PMID: 34453261    Free PMC article.
Recent advances in immune therapies for gastric cancer.
Matthew J Olnes, Holly A Martinson.
Cancer Gene Ther, 2021 Mar 06; 28(9). PMID: 33664460    Free PMC article.
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
James McAuliffe, Hok Fung Chan, +9 authors, Benoit J Van den Eynde.
J Immunother Cancer, 2021 Sep 05; 9(9). PMID: 34479921    Free PMC article.
Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors.
Megan L Burger, Amanda M Cruz, +22 authors, Tyler Jacks.
Cell, 2021 Sep 18; 184(19). PMID: 34534464    Free PMC article.
Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward.
Maria Rain Jennings, David Munn, John Blazeck.
J Immunother Cancer, 2021 Oct 21; 9(10). PMID: 34667078    Free PMC article.
A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response.
Kelli A Connolly, Manik Kuchroo, +19 authors, Nikhil S Joshi.
Sci Immunol, 2021 Oct 02; 6(64). PMID: 34597124    Free PMC article.
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Ali R Jazirehi.
Int J Mol Sci, 2021 Nov 14; 22(21). PMID: 34769156    Free PMC article.
Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets.
Michelle H Teplensky, Jasper W Dittmar, +4 authors, Chad A Mirkin.
Adv Healthc Mater, 2021 Sep 09; 10(22). PMID: 34494382    Free PMC article.
CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer.
Yoshinori Yanai, Takeo Kosaka, +7 authors, Mototsugu Oya.
Sci Rep, 2021 Nov 20; 11(1). PMID: 34795362    Free PMC article.
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.
Haley du Bois, Taylor A Heim, Amanda W Lund.
Sci Immunol, 2021 Sep 14; 6(63). PMID: 34516744    Free PMC article.
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth.
Alyssa K Kosmides, John-William Sidhom, +2 authors, Jonathan P Schneck.
ACS Nano, 2017 Jun 08; 11(6). PMID: 28589725    Free PMC article.
Metabolic interventions: A new insight into the cancer immunotherapy.
Tao Yu, Tianhan Dong, +4 authors, Xiongbin Lu.
Arch Biochem Biophys, 2020 Nov 05; 697. PMID: 33144083    Free PMC article.
Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.
Jeong Hun Kim, Won Suk Lee, +10 authors, Chan Kim.
Oncoimmunology, 2021 Dec 04; 10(1). PMID: 34858729    Free PMC article.
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.
Tadahiro Shoji, Shunsuke Tatsuki, +7 authors, Hiroaki Itamochi.
Cancers (Basel), 2021 Dec 11; 13(23). PMID: 34885229    Free PMC article.
Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus.
Leila Sawada, Antonio Carlos Rosário Vallinoto, Igor Brasil-Costa.
Biomolecules, 2021 Dec 25; 11(12). PMID: 34944437    Free PMC article.
Fighting in a wasteland: deleterious metabolites and antitumor immunity.
McLane J Watson, Greg M Delgoffe.
J Clin Invest, 2022 Jan 19; 132(2). PMID: 35040434    Free PMC article.
Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues.
Namiko Ikeda, Daiki Kato, +11 authors, Takayuki Nakagawa.
J Vet Med Sci, 2021 Oct 26; 83(12). PMID: 34690223    Free PMC article.
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Florent Peyraud, Jean-Philippe Guegan, +3 authors, Antoine Italiano.
Front Immunol, 2022 Feb 18; 13. PMID: 35173722    Free PMC article.
TCR-sequencing in cancer and autoimmunity: barcodes and beyond.
Kristen E Pauken, Kaitlyn A Lagattuta, +6 authors, Arlene H Sharpe.
Trends Immunol, 2022 Jan 30; 43(3). PMID: 35090787    Free PMC article.
New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment.
Ji-Yong Sung, Jae-Ho Cheong.
Cells, 2022 Mar 11; 11(5). PMID: 35269390    Free PMC article.
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Aung Naing, John D Powderly, +11 authors, Jordan D Berlin.
J Immunother Cancer, 2022 Mar 16; 10(3). PMID: 35288468    Free PMC article.
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
Sandra Kang, Bassel F El-Rayes, Mehmet Akce.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406520    Free PMC article.
The Role of NcRNAs to Regulate Immune Checkpoints in Cancer.
Yicun Jiang, Leilei Zhao, +4 authors, Xiaoyan Yang.
Front Immunol, 2022 Apr 26; 13. PMID: 35464451    Free PMC article.
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.
Sarah E Fenton, Jeffrey A Sosman, Sunandana Chandra.
Cancer Drug Resist, 2019 Sep 19; 2(3). PMID: 35582566    Free PMC article.
Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention.
Wenjie Zhang, Jie Zhang, +4 authors, Dong Tang.
J Cancer Res Clin Oncol, 2022 Jun 07;. PMID: 35661254